Medical device development company Evolve Medtech Partners announced on Wednesday that Rob Abrams has joined the company's team.
With more than 30 years of experience in biomedical device product development, research, operational management, new business development and strategic investments, Abrams currently serves as a senior global business development and strategy executive with Kaneka Corp.
Abrams previously served as an operating partner at Sanderling Ventures and CEO of Pulsar Vascular, which was acquired by Johnson & Johnson.
Before he joined Sanderling, Abrams was group vice president of new business development for cardiovascular at Boston Scientific and has also served in various roles at Target Therapeutics, Localmed, Howmedica, and Guidant. lve-medtech.com
Bayer and Broad Institute extend cardiovascular research alliance to advance precision therapies
CirCode Biomed's IND application for HM2002 receives FDA clearance
CeleCor Therapeutics completes Phase 3 trial of new anti-platelet agent for heart attack
Sarepta receives UK approval to continue dosing in ELEVIDYS ENVISION study
Ionis reports positive Phase 3 results for olezarsen in moderate hypertriglyceridemia
Nordic Bioscience launches new Endotrophin assay
AbbVie and ADARx Pharmaceuticals partner on next-generation siRNA therapies
Otsuka's leukaemia drug ponatinib launched on Fangzhou platform
FDA accepts Novo Nordisk's filing application for oral semaglutide 25 mg
Avacta Therapeutics reports positive Phase 1 data for lead candidate
Innovent's limertinib receives Chinese regulatory approval for first-line treatment of lung cancer
Primo Biotechnology's Taoyuan facility granted PIC/S GMP Certification
Renibus Therapeutics completes RBT-1 Phase 3 clinical trial enrolment